Stocks
By market cap · 34 stocks
- 1
PTC TherapeuticsPTCTRare-disease drugmaker spanning PKU, DMD, and gene therapy$5.85B−2.41% - 2
Legend Biotech (ADR)LEGNCARVYKTI commercializer and CAR-T developer$3.68B−3.05% - 3
PrecigenPGENPAPZIMEOS commercial-stage gene and cell therapy developer$2.48B−3.55% - 4
Mesoblast (ADR)MESODeveloper of allogeneic cell medicines$2.26B−3.91% - 5
Immunocore (ADR)IMCRImmTAX therapy developer and KIMMTRAK marketer$1.86B−0.33% - 6
SL ScienceSLBTPreclinical immune-cell therapies and Taiwan exosome products$1.51B+2.27% - 7
Monte Rosa TherapeuticsGLUEMolecular glue degrader drug developer$1.13B−6.60% - 8
Solid BiosciencesSLDBGene therapies for rare muscle and cardiac diseases$961.9M−3.46% - 9
Design TherapeuticsDSGNGeneTAC developer for inherited genetic diseases$943.7M−0.98% - 10
MiMedxMDXGMaker of placental-tissue allografts for wound care$655.9M−0.44% - 11
Prime MedicinePRMEPrime Editing genetic therapy developer$652.0M−0.77% - 12
ProKidneyPROKAutologous cell therapy developer for advanced kidney disease$615.3M+0.82% - 13
Capricor TherapeuticsCAPRDeramiocel-focused DMD cell-therapy developer$551.5M−4.57% - 14
Artiva BiotherapeuticsARTVDeveloper of off-the-shelf NK-cell therapies$542.2M−7.20% - 15
Kyverna TherapeuticsKYTXAutologous CAR-T developer for autoimmune diseases$508.9M−3.24% - 16
FateFATEOff-the-shelf iPSC CAR T/NK pipeline$283.2M−4.92% - 17
Cartesian TherapeuticsRNACmRNA cell therapy developer for autoimmune disease$282.1M−4.01% - 18
Lineage Cell TherapeuticsLCTXDeveloper of allogeneic cell-replacement therapies$276.7M−3.88% - 19
Entrada TherapeuticsTRDADeveloper of exon-skipping therapies for Duchenne muscular dystrophy$271.7M−3.99% - 20
Niagen BioscienceNAGENAD+ science and Niagen supplements$262.0M+2.65% - 21
MaxCyteMXCTFlow electroporation cell-engineering platform$130.7M−4.30% - 22
Atara BiotherapeuticsATRAPartner-led EBV-targeted T-cell therapy support$82.9M−1.30% - 23
CelularityCELUPlacenta-derived cellular-medicine platforms$45.7M−25.24% - 24
Marker TherapeuticsMRKRMulti-antigen T-cell therapies for cancer$22.8M−7.53% - 25
EnlivexENLVAllocetra cell therapy and RAIN treasury$22.7M−7.12% - 26
LongeveronLGVNDeveloper of laromestrocel cell therapy$20.5M−1.18% - 27
Genenta Science (ADR)GNTATumor-targeted gene therapy and Italian industrial investments$19.1M+1.95% - 28
PluriPLURCell-expansion platform for therapies and cultivated foods$16.5M−1.96% - 29
KALA BIOKALABiotech AI platform and retained biologics assets$13.3M−15.02% - 30
Satellos BioscienceMSLEOral muscle-repair therapy developer for Duchenne muscular dystrophy$11.2M−7.54% - 31
CytoMed TherapeuticsGDTCDeveloper of off-the-shelf cancer cell therapies$10.9M−3.16% - 32
Xenetic BiosciencesXBIODeveloper of DNase cancer-treatment adjuncts$9.1M−0.25% - 33
BioRestorative TherapiesBRTXAutologous cell therapy developer for chronic disc disease$5.1M−2.86% - 34
Creative Medical TechnologyCELZDeveloper of regenerative cell therapies and CaverStem kits$2.9M+1.58%